ACAD(Acadia Pharmaceuticals Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $484.14M | $517.24M | $726.44M | $957.80M | $1.07B |
| 毛利润 | $473.30M | $507.07M | $684.80M | $875.96M | $982.51M |
| 营业利润 | −$170.44M | −$223.60M | −$73.38M | $230.79M | $104.81M |
| 净利润 | −$167.87M | −$215.97M | −$61.29M | $226.45M | $391.00M |
| 经营现金流 | −$125.66M | −$114.03M | $16.70M | $157.72M | $109.84M |
| 自由现金流 | −$126.78M | −$114.03M | $16.65M | $157.20M | $105.15M |
| 摊薄每股收益 | $-1.05 | $-1.34 | $-0.37 | $1.36 | $2.30 |